OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per Share
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
The company's chairman bought more shares of OKYO at $1.40 each, showing he believes in the company. When leaders put their own money in, it can suggest they think the business has a good future ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.